The company acquires and licenses technologies for the development of novel cancer immunotherapy products, with a current focus on Chimeric Antigen Receptor (CAR) engineered T cell (CAR-T) technology. Mustang Bio is conducting Phase I clinical trials for CAR-T therapies targeting multiple cancers, including acute myeloid leukemia (AML) and brain cancer. Additionally, the company is actively involved in advancing gene therapies for rare genetic disorders and CAR-T therapies for solid tumors.